[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pituitary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pituitary":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100543258","phase-4-postop-pain-management-in-pituitary-tumour-patients-100543258",false,"NCT06353529","Postop Pain Management in Pituitary Tumour Patients","Effect of Sphenopalatine Ganglion Block With Bupivacaine on Postoperative Pain in Patients Undergoing Endoscopic Pituitary Adenoma Resection","POPPY","Inclusion Criteria:\n\n* adult patients (18 yrs or older)\n* undergoing endonasal pituitary adenoma resection\n\nExclusion Criteria:\n\n* Patients with pre-existing chronic pain conditions requiring antidepressants (serotonin reuptake inhibitors), benzodiazepines, gabapentin, or opioid drugs\n* contraindications to the performance of SPGB such as known allergy to used medications\n* chronic alcohol abuse\n* uncontrolled systemic arterial hypertension\n* severe kidney or liver diseases\n* cardiomyopathies or sustained cardiac arrhythmias (permanent paroxystic atrial fibrillation or other sustained supraventricular rhythmic anomalies)","ALL","18 Years","100 Years",{"count":21,"type":22},108,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","To assess the benefit of using an additional nerve block during minimally invasive pituitary surgery, to improve pain management after surgery. The medication (Bupivacaine) or a placebo (saline) will be injected during surgery and patients will be asked about their level of pain at multiple time points in the first 24 hours following surgery. Some patients will be randomized to a third, sham group that do not receive any additional injection. The aim is to improve patient outcomes and reduce the need for pain medication after surgery.",[28,29],"Pituitary","Pain, Postoperative",[31,32,33],"Nerve block","Bupivacaine","Sphenopalatine Ganglion","RECRUITING","2026-03-10",{"date":37,"type":38},"2026-03-12","ACTUAL",{"date":40,"type":38},"2024-11-25",{"date":42,"type":22},"2026-07",{"name":44,"class":45},"Hamilton Health Sciences Corporation","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100485443","clinics-and-epidemiology-of-pituitary-diseases-in-modena-area-population-100485443","NCT05601141","Clinics and Epidemiology of Pituitary Diseases in Modena Area Population","Pituitary Diseases in Modena Population: Clinical and Epidemiological Data Register of Pituitary Patients Attending the Unit of Endocrinology of Azienda Ospedaliero-Universitaria of Modena (DataPit)","DataPit","Inclusion Criteria:\n\n* subjects affected by pituitary disorders who attended Unit of Endocrinology of Azienza Ospedaliero-Universitaria di Modena\n\nExclusion Criteria:\n\n* subjects under 18 years old",{"count":56,"type":22},1500,"10 Years","OBSERVATIONAL","This is an observational, longitudinal, single-center study.\n\nThe study is divided in two phases:\n\n* FIRST PHASE (retrospective): registration of all patients affected by pituitary disorders followed at the Unit of Endocrinology of Azienda Ospedaliero-Universitaria of Modena\n* SECOND PHASE (prospective): enrollment of all patients affected by pituitary disorders who attend the Unit of Endocrinology of the Azienda Ospedaliero-Universitaria of Modena.\n\nAn anonymized database will be created to collect the data of the patients. In particular, the data collected for each patient will include: personal data, data relating to pituitary pathology, symptoms at diagnosis, physical examination, radiological imaging, visual field data, data on surgical intervention, data on histological examination, biohumoral examinations, hormone tests, densitometric data, data on replacement therapies, medical therapies or other pharmacological therapies, data on comorbidities.",[28],"2025-03-12",{"date":63,"type":38},"2025-03-14",{"date":65,"type":38},"2022-10-24",{"date":67,"type":22},"2031-10-24",{"name":69,"class":45},"Azienda Ospedaliero-Universitaria di Modena",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":46},"100562748","clinical-pathological-evaluation-of-pit-nets-100562748","NCT06607198","Clinical-pathological Evaluation of Pit-NETs","Clinical-pathological Assessment of Pit-NETs: Data From a Large Multicenter Patients Cohort","PitNET2024","Inclusion Criteria:\n\n* Consecutive patients older than 18 years;\n* availability of tumor samples for the required pathology analyses;\n* clinico-radiological follow-up of at least 5-10 years\n\nExclusion Criteria:\n\n\\- Not applicable for this study",{"count":79,"type":22},940,"Pituitary adenomas, namely pituitary neuroendocrine tumors (PitNETs), are recognized as rare neoplasia by national and international institutions.\n\nAlbeit most PitNETs are slow-growing with an indolent behavior, about one-third do not achieve biochemical control, recur, re-grow, and resist conventional treatments.\n\nThe predictors of aggressive behavior have not been identified for PitNETs. In 2013 Trouillas and coworkers developed a five tiered clinicopathological score by mixing histopathological data and clinico-radiological evidence of invasion. This system proved of prognostic value. Nonetheless, unlike for NET of gut and lung, no formal grading and\u002For staging tools were developed. In addition, PitNETs have not been thoroughly investigated by radiomics to predict clinical behavior, nor have druggable pathways been elucidated in PitNET cells to unveil new potential therapeutic approaches.\n\nThe first aim of this project is to define grading and staging tools for PitNETs based on: i) lineage-specific transcription factors ; ii) cell type specification by hormone production (prolactin, TSH, LH, FSH, ACTH, GH or none); iii) integration of standard radiological measures with recognized tools for clinical and pathological staging.\n\nThe second aim of this project is to investigate radiomics features as predictors of PitNETs behavior, prognosis, and treatment outcome.\n\nThe third aim of this project is to investigate whether the expression of molecular biomarkers \\[Vascular Endothelial Growth Factor (VEGF), Epithelial Growth Factor Receptor (EGFR), somatostatin receptors 1-5 (SSTRs), Fibroblast Growth Factor (FGF), mTOR (mammalian target of rapamycin), Programmed cells Death 1 (PD1) and its ligands (PD-L1), and Cytotoxic T Lymphocyte Associated protein 4 (CTLA4)\\] may impact on patients prognosis. Identifying new molecular pathways may help fine-tune and schedule the emerging targeted therapies for aggressive PitNETs, including mTOR inhibitors, VEGF, EGFR, and immune check-point inhibitors.\n\nThis study will investigate a large multicenter retrospective series of 740 PitNET patients and a prospective cohort of 200 patients to reach these objectives.",[28,82,83],"Cancer","Neuroendocrine Tumors","NOT_YET_RECRUITING","2024-09-19",{"date":87,"type":38},"2024-09-23",{"date":89,"type":22},"2024-10-01",{"date":91,"type":22},"2026-10-01",{"name":93,"class":45},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]